Lilly's Weight-Loss Drug Improved Sleep Apnea in Studies.

ELI Lilly & Co.; SLEEP apnea syndromes; ANTIOBESITY agents; SPARE parts; MEDICARE beneficiaries

Eli Lilly & Co.'s weight-loss drug Zepbound has shown promising results in improving sleep-related breathing problems in patients with obstructive sleep apnea, a condition closely linked to obesity. In two late-stage trials, Zepbound reduced the number of breathing interruptions during sleep by up to 63% and resulted in weight loss of up to 20% in patients. If approved, Zepbound could potentially receive reimbursement from Medicare, making it more accessible to older individuals with sleep apnea. The approval could also position Lilly as a competitor to Novo Nordisk A/S in the weight-loss medication market. However, it is unlikely that Zepbound and other drugs will completely eliminate sleep apnea. [Extracted from the article]

Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)